U.S. Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
82.77+0.53 (+0.64%)
At close: 5:36PM CEST
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Full screen
Previous Close82.24
Open82.00
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range81.77 - 83.32
52 Week Range66.72 - 92.97
Volume2,530,317
Avg. Volume2,489,360
Market Cap100.97B
Beta0.74
PE Ratio (TTM)11.45
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield3.30 (3.50%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Reuters7 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
    Zacks3 days ago

    AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

    AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

  • American City Business Journals6 days ago

    Emergent acquires Sanofi smallpox vaccine in deal worth up to $125 million

    Gaithersburg biotech Emergent BioSolutions is acquiring French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million. The company will pay $97.5 million up front to Sanofi and an additional $27.5 million in near-term regulatory and manufacturing milestone payments. Emergent will add the only smallpox vaccine licensed by the Food and Drug Administration to its existing portfolio of medical countermeasures to bioterrorism threats.